Category: ACN Newswire

Biologics License Application for Subcutaneous Formulation of “LEQEMBI(R)” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China

TOKYO and CAMBRIDGE, Mass., Feb 10, 2026 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the

More